Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 74, Issue 6, 2013, Pages

  Storch, Eric A ^a   Goddard, Andrew W ^b   Grant, Jon E ^c   De Nadai, Alessandro S ^a   Goodman, Wayne K ^d   Mutch, P Jane ^a   Medlock, Carla ^b   Odlaug, Brian ^c,e   McDougle, Christopher J ^f   Murphy, Tanya K ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PALIPERIDONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; AGITATION; ANXIETY; APPETITE; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DSM-IV; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; INSOMNIA; MALE; MUSCLE RIGIDITY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TINNITUS; TREATMENT RESISTANT OBSESSIVE COMPULSIVE DISORDER; URINE INCONTINENCE; WEIGHT GAIN; XEROSTOMIA; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 84879567435     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08278     Document Type: Article

References (29)

1. Adam Y, Meinlschmidt G, Gloster AT, et al. Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. Soc Psychiatry Psychiatr Epidemiol. 2012;47(3):339-349. doi:10.107/s0127-010-037-5 PubMed
2. Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessivecompulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53-63. doi:10.1038/mp.208.94 PubMed
3. Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin North Am. 1992;15(4):743-758. PubMed
4. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry. 1999;60(2):101-106. doi:10.408/JCP.v60n0206 PubMed
5. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22(3):309-317. doi:10.1097/04714-202060-012 PubMed
6. Fineberg NA, Brown A, Reghunandanan S, et al. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2012;15(8):1173-1191. doi:10.1017/S1461457101829 PubMed
7. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-632. doi:10.1038/sj.mp.401823 PubMed
8. Dold M, Aigner M, Lanzenberger R, et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2012:1-18. doi:10.1017/S1461457120740 PubMed
9. Erzegovesi S, Guglielmo E, Siliprandi F, et al. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15(1):69-74. doi:10.1016/j.euroneuro.204.04.04 PubMed
10. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebocontrolled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794-801. doi:10.101/archpsyc.57.8.794 PubMed
11. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother. 2009;9(1):9-31. doi:10.1586/14737175.9.1.9 PubMed
12. Wang SM, Han C, Lee SJ, et al. Paliperidone: a review of clinical trial data and clinical implications. Clin Drug Investig. 2012;32(8):497-512. PubMed
13. Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70(10):1295-1317. doi:10.2165/1204840-0-0 PubMed
14. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSMIV Axis I Disorders, Clinician Version-(SCID-CV). Washington, DC: American Psychiatric Press, Inc; 1996.
15. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. doi:10.101/archpsyc.1989.01810104807 PubMed
16. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. 2: validity. Arch Gen Psychiatry. 1989;46(11):1012-1016. doi:10.101/archpsyc.1989.01810105408 PubMed
17. Koran LM, Hanna GL, Hollander E, et al; American Psychiatric Association. Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder. Am J Psychiatry. 2007;164(suppl):5-53. PubMed
18. Denys D, Fineberg N, Carey PD, et al. Quetiapine addition in obsessivecompulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry. 2007;61(3):412-414. doi:10.1016/j.biopsych.206.12.014 PubMed
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised Edition. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
21. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968;5(2):257-282. PubMed
22. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-381. PubMed
23. Cooper H, Hedges LV, Valentine JC. The Handbook of Research Synthesis and Meta-Analysis. New York, NY: Russell Sage Foundation Publications; 2009.
24. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
25. SAS Institute. SAS/STAT User's Guide (version 9.2). Cary, NC: SAS Institute, Inc; 2008.
26. Storch EA, Lewin AB, De Nadai AS, et al. Defining treatment response and remission in obsessive-compulsive disorder: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. J Am Acad Child Adolesc Psychiatry. 2010;49(7):708-717. PubMed
27. Barnard J, Rubin DB. Miscellanea: small-sample degrees of freedom with multiple imputation. Biometrika. 1999;86(4):948-955. doi:10.1093/biomet/86.4.948
28. Cameron A. Kurtosis. In: Lewis-Beck M, Bryman A, Liao T, eds. Encyclopedia of Social Science Research Methods. New York, NY: Sage Publications, Inc; 2004. doi:10.4135/9781412950589.n467
29. Hollander E, Baldini Rossi N, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebocontrolled study. Int J Neuropsychopharmacol. 2003;6(4):397-401. doi:10.1017/S14614570303730 PubMed